Iovance Biotherapeutics Inc (IOVA) — Net Asset Quality Index
Iovance Biotherapeutics Inc (IOVA) has a Net Asset Quality Index of 77.6% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $904.95 Million minus total liabilities of $202.66 Million yields net assets of $702.29 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check Iovance Biotherapeutics Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
Iovance Biotherapeutics Inc Net Asset Quality Index Over Time (2008–2024)
This chart shows how Iovance Biotherapeutics Inc's Net Asset Quality Index has evolved across 17 annual periods from 2008 to 2024. As of September 2025, the index stands at 77.6%, representing net assets of $702.29 Million against total assets of $904.95 Million USD. See Iovance Biotherapeutics Inc (IOVA) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for Iovance Biotherapeutics Inc (2008–2024)
The table below presents the year-by-year Net Asset Quality Index for Iovance Biotherapeutics Inc from 2008 to 2024, covering 17 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Iovance Biotherapeutics Inc stock valuation.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 78.0% | $710.40 Million | $910.43 Million | $200.02 Million | ▲ +3.1 pp |
| 2023 | 74.9% | $584.61 Million | $780.35 Million | $195.74 Million | ▼ -0.3 pp |
| 2022 | 75.2% | $499.64 Million | $663.98 Million | $164.34 Million | ▼ -4.7 pp |
| 2021 | 80.0% | $621.66 Million | $777.33 Million | $155.67 Million | ▼ -5.5 pp |
| 2020 | 85.4% | $656.50 Million | $768.46 Million | $111.96 Million | ▼ -1.3 pp |
| 2019 | 86.7% | $298.97 Million | $344.65 Million | $45.68 Million | ▼ -10.2 pp |
| 2018 | 97.0% | $466.19 Million | $480.82 Million | $14.63 Million | ▲ +3.3 pp |
| 2017 | 93.6% | $145.48 Million | $155.37 Million | $9.89 Million | ▼ -3.5 pp |
| 2016 | 97.1% | $166.92 Million | $171.89 Million | $4.97 Million | ▼ -1.3 pp |
| 2015 | 98.5% | $104.02 Million | $105.65 Million | $1.63 Million | ▲ +2.0 pp |
| 2014 | 96.4% | $44.85 Million | $46.51 Million | $1.66 Million | ▲ +7.8 pp |
| 2013 | 88.6% | $17.60 Million | $19.87 Million | $2.27 Million | ▲ +38573.2 pp |
| 2012 | -38484.6% | $-11.32 Million | $29.41K | $11.35 Million | ▼ -36236.1 pp |
| 2011 | -2248.5% | $-12.78 Million | $568.43K | $13.35 Million | ▼ -2292.1 pp |
| 2010 | 43.7% | $638.09K | $1.46 Million | $822.87K | ▲ +183.7 pp |
| 2009 | -140.0% | $-13.49K | $9.63K | $23.12K | ▼ -180.7 pp |
| 2008 | 40.7% | $2.28K | $5.61K | $3.33K | — |